^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:MEDI4276 (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Ann Oncol
    Title:

    Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer

    Excerpt:
    This was a phase 1 dose escalation trial in patients with advanced HER2+ breast or gastric cancer that was relapsed or refractory to standard therapy….In the as-treated population, there was 1 CR (0.5 mg/kg; breast), 1 PR (0.6 mg/kg; breast), and 12 (28%) patients with SD....MEDI4276 has clinical activity, but with increased toxicity at higher doses.
    DOI:
    https://doi.org/10.1093/annonc/mdy048.005
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2+ Advanced Breast or Gastric Cancer

    Published date:
    05/27/2021
    Excerpt:
    This was a first-in-human, dose-escalation clinical trial in patients with HER2+ advanced or metastatic breast cancer (BC) or gastric cancer...In the as-treated population, there was 1 complete response (0.5 mg/kg; BC), and 2 partial responses (0.6 and 0.75 mg/kg; BC)...
    DOI:
    10.1158/1535-7163.MCT-20-0014